Resverlogix Receives Health Canada Approval for Fabry Disease Clinical Trial with Apabetalone

June 2, 2017

Health Canada has granted approval to Resverlogix to proceed with a clinical trial of apabetalone in Fabry disease.

The disease is caused by a mutation in the GLA gene leading to a deficiency in the alpha galactosidase-A enzyme that breaks down a fatty substance called Gb3. This leads to abnormal deposits of Gb3 in blood vessel walls and tissues throughout the body that can damage major organs and shorten lifespan.

Apabetalone (RVX-208) is a selective BET (bromodomain and extra-terminal) inhibitor that can regulate disease-causing genes.

View today's stories